Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 8/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 4/20 | 0.46 |
| ▸ | GCGR | P47871 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4375430 | 0.93 | HRH3 (0.48) | HRH3CNR2DRD3CNR1GCGR | |
| SCHEMBL7919389 | 0.81 | MEN1 (0.64) | HRH3MEN1KMT2A | |
| SCHEMBL4378514 | 0.81 | GPR52 (0.45) | HRH3GCGRMEN1KMT2AGPR52 | |
| Hydrochloric Acid SCHEMBL27556211 | 0.80 | MEN1 (0.62) | HRH3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27531033 | 0.80 | MEN1 (0.62) | HRH3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27491721 | 0.80 | MEN1 (0.62) | HRH3MEN1KMT2A | |
| SCHEMBL4377273 | 0.78 | GPR52 (0.44) | HRH3MEN1KMT2AGPR52 | |
| SCHEMBL4375991 | 0.76 | GPR52 (0.44) | HRH3MEN1KMT2AGPR52SLC6A3 | |
| SCHEMBL4379001 | 0.76 | MAOB (0.45) | MEN1KMT2A | |
| SCHEMBL4379112 | 0.75 | P2RX7 (0.53) | DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | claimed |
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | HRH3 1/4885CNR2 20/4885DRD3 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.